Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02187302
Title CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cerulean Pharma Inc.
Age Groups: adult
Covered Countries USA

No variant requirements are available.